Immune Homeostasis in Sepsis and Septic Shock

Launched by CHARLES UNIVERSITY, CZECH REPUBLIC · Jun 24, 2020

Keywords

ClinConnect Summary

This clinical trial, titled "Immune Homeostasis in Sepsis and Septic Shock," is studying how the immune system responds in patients who are experiencing sepsis or septic shock. Sepsis is a serious condition caused by the body's response to an infection, which can lead to a weakened immune system. Researchers want to learn more about the changes in the immune response during this time to help develop better treatments. The study involves taking samples from participants and analyzing their immune cells and proteins to understand these dynamics better.

To participate in this trial, individuals must be at least 18 years old and diagnosed with sepsis or septic shock within the first 24 hours of their condition. Unfortunately, those with certain immune system disorders or active cancers will not be eligible. Participants will be asked to give their consent and may undergo tests to help researchers gather important information about their immune responses. This study is currently recruiting participants of all genders, and it aims to enhance our understanding of sepsis to improve patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • sepsis/septic shock (SEPSIS-3)
• • age ≥18
• • informed consent
• • inclusion within first 24hrs after development/diagnosis of septic shock
• Exclusion Criteria:
• • disagreement of the patient or legal representative with the entry into the study
• • patients with primary or secondary immunodeficiency
• • presence of active haematological malignancy or an active non-haematological malignancy